CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant

Takuto Takahashi1,2,3, Angela R. Smith2, Pamala A. Jacobson3, Abeer F. Alharbi3, James Fisher3, Nathan T. Rubin4, and Mark N. Kirstein3

1Division of Hematology and Oncology, 2Division of Blood and Marrow Transplant, Department of Pediatrics, 3Department of Experimental and Clinical Pharmacology, and 4Department of Masonic Cancer Center Biostatistics Core, University of Minnesota, Minneapolis, MN, USA

Abstract. Fungal CYP51A (14α-sterol demethylase) is the target of an azole antifungal, voriconazole (VCZ), which also partially inhibits human CYP51A1. Hepatotoxicity is a common adverse effect of azoles, which is reported to be caused by altered gene expressions secondary to cholesterol synthesis inhibition by azoles. This is a post-hoc analysis of a previously conducted phase 1 dose-finding study of prophylactic VCZ in 56 pediatric hematopoietic cell transplant recipients. We explored an association between variants in human CYP51A1 (rs2282976 and rs6465348) and VCZ-induced hepatotoxicity. Genotype A/G or G/G in rs6465348 showed lower odds of hepatotoxicity after adjusting for VCZ area-under-the-curve (OR: 0.10, 95% CI: 0.01 – 0.79, vs. A/A).

What this study adds
– The single nucleotide variant of rs6465348 located in CYP51A1 gene may render protection against voriconazole-induced hepatotoxicity among pediatric hematopoietic-cell transplantation recipients.
Materials and methods

Study setting

We conducted a post-hoc analysis of pediatric HCT patients aged ≤ 21 years enrolled in a single-institution, phase I dose-finding study of intravenous VCZ (NCT02227797) in pediatric HCT recipients conducted at the University of Minnesota from 2015 to 2017. Children with pre-existing kidney or hepatic dysfunction were not eligible to participate in the study. The details of the study’s methodology were published previously [4]. A total of 58 participants with evaluable VCZ pharmacokinetic and the genotype data, of the 65 study participants, were included in this analysis (i.e., 6 had no pharmacokinetic data, and 1 no genotype data). The study was approved by the University of Minnesota Institutional Review Board and the Masonic Cancer Center Protocol Review Committee, and all participants and/or parents or guardians provided informed consent.

Outcomes

The primary outcome was VCZ-induced hepatotoxicity, which was defined as a liver dysfunction of any grade attributed to VCZ within the first week of its use according to the Common Terminology Criteria for Adverse Events version 4, namely, total bilirubin level > 1.5-fold of the upper limit of normal (ULN), or AST or ALT > 3-fold ULN. Liver dysfunction was monitored at least twice a week.

Pharmacokinetic analysis

Varying doses of prophylactic intravenous VCZ (3 mg/kg/hour, every 12 hours) were initiated on the day after stem cell infusion (i.e., HCT). Intensive observational pharmacokinetic (PK) studies of VCZ were performed on days 5 – 7 including six time-points (i.e., 5 and 30 minutes; 1, 3, 6, and 9 hours) after infusion completion and immediately before the next infusion start. All concentrations of VCZ were above the limit of quantitation (0.025 mg/L) as measured by an LC-MS/MS assay [5]. A pharmacokinetic assessment of steady-state profiles was performed with non-compartmental analysis with a trapezoidal method by linear-up-log-down method as implemented in R (version 3.6.0) PKNCA package (version 0.8.5). If the last timepoint plasma specimens (i.e., immediately before the next dose) were not collected at precisely 12 hours after the start of the infusion, we estimated the last timepoint VCZ concentrations by extrapolating/interpolating concentrations based on linear best-fit regression estimates for elimination rates from at least 3 concentration timepoints closest to 12 hours. We excluded patients from analyses when their inter-/extrapolated VCZ area-under-the-curve (AUC) was > 20% of the AUC without inter-/extrapolation. Consequently, we excluded 2 patients, which led to a final study population of 56 patients.

Genotyping of candidate SNPs

Pre-transplant recipient germline genomic DNA extracted from the blood was examined by a custom Amplicon SNP panel at the University of Minnesota Genomics Center. CYP2C19 phenotype was determined according to the Clinical Pharmacogenomics Implementation Consortium guidelines [6]. We selected two SNPs in the CYP51A1 gene with a minor allele frequency of > 10%: rs6465348 (chr7:92113288, A>G, 3’-UTR variant) and rs2282976 (chr7:92132811, A>G, intron variant). Samples without a genotype call were excluded from the analyses (4 of 56 for rs6465348 and 6 of 56 for rs2282976). The minor allele frequencies were 39.4 and 4.0% for rs6465348 and rs2282976, respectively, and were both in Hardy-Weinberg equilibrium (p = 0.77 and 1.00, respectively). We reveal no relevant variants with either SNP in haplotype analysis.

Statistical analysis

Univariate analysis was performed by 2-sample t-test for numerical and χ²-test for categorical variables. Multivariate logistic regression analysis was performed to assess the association of CYP51A1 SNPs and liver toxicity of any grade, while adjusting for VCZ AUC (treated as a continuous variable). Firth method was used because of the small event proportion in our cohort. Without any information on the clinical consequence of
the variants, we tested the effect of the variants both in dominant and recessive models. rs2282976 is tested in a recessive model because there were no patients with homozygous minor alleles. All statistical analyses are conducted by using R software (version 3.5.3).

## Results

Of the 56 children in the final analysis, the mean age was 9.4 years (SD 6.5), and 64% were male (Table 1). Hepatotoxicity of any grade was observed in 7 patients (13%); 2 with grade 3 increased AST and/or ALT, and 5 with isolated hyperbilirubinemia (median grade 3, range 1 – 3). The most common HCT indication was acute leukemia (48%). No significant association was observed on hepatotoxicity by age, gender, CYP2C19 phenotype, disease, or VCZ AUC by univariate analysis (p = 0.34, 0.67, 0.95, 0.21, and 0.24, respectively) (Table 1). In the multivariate logistic regression model for rs6465348 genotypes adjusting for VCZ AUC, the variants in the dominant model showed significantly lower odds of hepatotoxicity in comparison to the homozygous wild-allele (A/G or G/G vs. A/A; odds ratio: 0.10, 95% CI: 0.01 – 0.79, p = 0.03). In this model, VCZ AUC was approaching significance with toxicity (odds ratio: 1.02, 95% CI: 1.00 – 1.05, p = 0.06) (Table 2). No significant associa-

---

### Table 1. Patient characteristics and univariate analysis.

| Age (years), mean (SD) | Total (n = 56) | Hepatotoxicity (n = 49) | Present (n = 7) | p-value |
|------------------------|---------------|------------------------|----------------|---------|
| 9.4 (6.5) | 9.1 (6.6) | 11.7 (5.6) | | 0.33 |
| Male sex, n (%) | 36 (64%) | 31 (63%) | 5 (71%) | | 1.00 |
| CYP2C19 phenotype, n (%) | | | | |
| Poor | 1 (2%) | 1 (2%) | 0 |
| Intermediate | 13 (23%) | 11 (33%) | 2 (29%) |
| Normal | 29 (52%) | 26 (53%) | 3 (43%) |
| Rapid | 12 (21%) | 10 (30%) | 2 (29%) |
| Ultra-rapid | 1 (2%) | 1 (2%) | 0 |
| rs6465348 | | | | |
| A/A | 19 (34%) | 14 (39%) | 5 (71%) | 0.14 |
| A/G | 25 (45%) | 23 (47%) | 2 (29%) |
| G/G | 8 (14%) | 8 (16%) | 0 |
| No calla | 4 (7%) | 4 (8%) | 0 |
| rs2282976 | | | | |
| A/A | 46 (82%) | 42 (86%) | 4 (57%) | 0.17 |
| A/G | 4 (7%) | 3 (6%) | 1 (14%) |
| No calla | 6 (11%) | 4 (8%) | 2 (29%) |
| Drug-drug interactions, n (%) | | | | |
| Pantoprazole | 52 (93%) | 45 (92%) | 7 (100%) | 1.00 |
| Corticosteroids | 5 (9%) | 5 (10%) | 0 | 0.86 |
| Drugs listed in FDA labelb | 0 | 0 | 0 | . |
| Indications, n (%) | | | | |
| Acute leukemia | 25 (45%) | 22 (45%) | 3 (43%) |
| Aplastic anemia | 8 (14%) | 7 (14%) | 1 (14%) |
| Myelodysplastic syndrome | 6 (11%) | 5 (10%) | 1 (14%) |
| Others | 17 (30%) | 15 (31%) | 2 (29%) |
| VCZ dose (mg/kg), mean (SD) | 8.2 (2.0) | 8.3 (2.0) | 7.8 (1.9) | 0.50 |
| VCZ trough (mg/L), mean (SD) | 1.9 (1.9) | 1.9 (1.9) | 1.7 (1.8) | 0.79 |
| VCZ AUC (mg×h/L), mean (SD) | 42.1 (35.9) | 40.4 (33.2) | 54.5 (52.4) | 0.33 |
| VCZ AUC, dose normalized (mg×h/L)/(mg/kg), mean (SD) | 5.2 (4.0) | 5.1 (3.8) | 6.5 (5.2) | 0.37 |

SD = standard deviation; FDA = the US Food and Drug Administration; VCZ = voriconazole; AUC = area-under-the-curve. aNo reliable genotype call was made by the laboratory; bincludes the drugs listed under “Drug Interactions: Effects of other drugs on voriconazole” in the FDA package insert.
A potential novel link between a CYP51A1 variant (rs6465348) and a lower incidence of hepatotoxicity with VCZ use can make individuals less prone to impairment effect on cholesterol synthesis secondary to CYP51A1 inhibition by VCZ. This protection against azole-induced cholesterol pathway suppression can consequently prevent azole-induced hepatotoxicity because of their interconnection by gene regulations. A gene expression analysis, using in-vivo and in-vitro mouse models for azole-induced hepatotoxicity, suggested that cholesterol synthesis inhibition upon exposure to azoles lead to compensatory overexpression of upstream regulatory genes for cholesterol pathway; these genes activate pathways involved in oxidative stress and cytokine production, which lead to hepatotoxicity [3].

A main limitation of this study is the small sample size. However, the use of VCZ AUC from an intensive PK study allowed an adjustment of variable VCZ exposure, which would otherwise be a major confounder in studies with a small sample size. This study was a hypothesis-driven exploratory study and did not assess the involvement of other potential causes of drug-induced hepatotoxicity (e.g., toxic metabolites, mitochondrial dysfunction, or apoptosis) [8].

We report a potential novel link between a CYP51A1 variant (rs6465348) and a lower incidence of hepatotoxicity with VCZ use. Future research should focus on validation of our findings in large patient cohorts with various demographic and disease characteristics, functional analysis of rs6465348, and exploration of its clinical utility.

**Acknowledgment**

We would like to acknowledge the assistance of the Clinical Pharmacology Shared Resource of the Masonic Cancer Center, designated by the National Cancer Institute, supported in part by P30 CA77598.

**Funding**

This work was supported by the Hematology Oncology Pharmacist Association (HOFA) Foundation (MNK), and the Department of Pediatrics, Division of Blood and Marrow Transplant, University of Minnesota (ARS).
Conflict of interest

Nothing to declare.

References

[1] Jin H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, Hui J, Zhou S. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016; 71: 1772-1785. CrossRef PubMed

[2] Warrilow AG, Parker JE, Kelly DE, Kelly SL. Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob Agents Chemother. 2013; 57: 1352-1360. CrossRef PubMed

[3] Park SM, Kang SJ, Choi MS, Kim S, Yoon S, Oh JH. Comparative omics analyses of hepatotoxicity induced by oral azole drugs in mice liver and primary hepatocytes. Toxicol Mech Methods. 2019; 29: 531-541. CrossRef PubMed

[4] Knight-Perry J, Jennissen C, Long SE, Hage S, DeFor TE, Chan WT, Fisher J, Kirstein MN, Smith AR. A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation. Bone Marrow Transplant. 2020; 55: 955-964. CrossRef PubMed

[5] Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, Bille J, Calandra T, Zanolari B, Marchetti O. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother. 2010; 54: 5303-5315. CrossRef PubMed

[6] Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agündez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2017; 102: 45-51. CrossRef PubMed

[7] Lewińska M, Zelenko U, Merzel F, Golic Grbaljnik S, Murray JC, Razdan D. Polymorphisms of CYP51A1 from cholesterol synthesis: associations with birth weight and maternal lipid levels and impact on CYP51 protein structure. PLoS One. 2013; 8: e82554. CrossRef PubMed

[8] Tarantino G, Di Minno MND, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol. 2009; 15: 2817-2833. CrossRef PubMed